



Immunomic Therapeutics, Inc.

Press Release

January 2, 2006

Immunomic Therapeutics, Inc.
9290 Gaither Road
Gaithersburg, MD 20877

Ph: 240-731-5232
Fax: 240-597-4061
info@immunomictherapeutics.com
www.immunomix.com

FOR IMMEDIATE RELEASE: January 2, 2006 (Gaithersburg, MD)

Immunomic Therapeutics Begins Operations in Earnest; Looks Forward to 2006

Gaithersburg, MD, January 2, 2006 /-- Immunomic Therapeutics, Inc. (ITI, www.immunomictherapeutics.com) announced today that it is officially starting operations today and that it has appointed Dr. Bill Hearl, most recently the Chief Scientific Officer of Capital Genomix, to be the President and CEO of ITI.

ITI has been organized for the expressed purpose of commercializing LAMP based vaccines as part of collaboration between Johns Hopkins University and Capital Genomix, Inc., a Maryland based biotechnology company. "Over the first few months of 2006 we will work with Johns Hopkins to work out terms of a license agreement. Once that work is complete we will begin looking to capture sub-licensees and collaborators to begin the commercialization process," said Dr. Hearl. According to Hearl, the Company expects to have the license completed and the first sub-license in place before the end of the year.


About Capital Genomix, Inc.

Capital Genomix, a biotechnology company located in Gaithersburg, Maryland, possesses two powerful and proprietary genomic and proteomic drug development technology platforms. Capital Genomix intends to couple these platforms – *GeneSystem320™* (*GS320™*) for analytical study of genes and gene expression and *ImmunoMouse™* for the development of specific antibodies against genetic sequences of biological significance – into a unified, end-to-end gene discovery, functional analysis and target validation system. Capital Genomix intends to utilize these technologies to enable biopharmaceutical collaborators to go from gene study and discovery through function analysis and target validation and directly to potential therapeutic agents and diagnostic targets. For additional information visit www.capitalgenomix.com.

About Immunomic Therapeutics

Immunomic Therapeutics, Inc. ("ITI") is a privately held biotechnology company headquartered in Gaithersburg, Maryland that is commercializing a portfolio of clinical applications based on "LAMP" vaccine technology. ITI offers access to LAMP – based vectors and novel vaccine design through license and collaborative research agreements. More information about ITI and LAMP technology can be obtained from www.immunomix.com or www.immunomictherapeutics.com.

This press release may contain forward looking statements regarding, among other matters, the Company's future prospects. Forward looking statements address matters that are subject to a number of risks and uncertainties that can cause actual results to differ materially. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of ITI's technologies, constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Future results of the Company will depend on a variety of factors, including the timing of significant orders, the ability of the Company to timely manufacture and deliver ordered products, the ability of the Company to bring new systems to market, the timing of new product releases by the Company's competitors and other competitive factors.



Immunomic Therapeutics, Inc.

Press Release

January 2, 2006

CONTACT:

Immunomic Therapeutics, Inc.
Bill Hearl, Ph.D., President & CEO
240-731-5232
bhearl@immunomictherapeutics.com